Key result
A purified FMDV type O vaccine concentrated via peggylation (82.8% recovery) maintained protective antibody titers in bovine calves for up to 20 weeks post-priming at a 6 µg/dose.
Why the study?
Pakistan produces non-purified FMD vaccine well below annual demand and lacked indigenous methods for FMDV concentration and purification.
A locally produced, peggylation-concentrated and chromatography-purified FMDV type O vaccine at 6 µg/dose provides protective immunity in bovine calves up to 20 weeks.
Purified local FMD vaccine elicits response in calves; leaves open scalability to close Pakistan's 145-million-dose annual gap.
Foot and Mouth Disease (FMD) is globally pandemic which badly affect the economics of livestock based countries like Pakistan. There are different types of Foot and Mouth Disease Virus (FMDV) among these types O is most prevalent in Pakistan. Recently Pakistan is producing approximately fifteen million doses of non-purified FMD vaccine against the demand of 160 million doses annually. More over the Pakistan is still striving for the development and optimization of concentration as well as purification of FMDV. The present project was designed to develop the technology for the purification of FMDV indigenously. The locally isolated and adapted FMDV type O virus was propagated on adherent culture of BHK-21cells to get final volume of virus one liter. This virus suspension was concentrated by peggylation as well as ultra-filtration method. The purification and quantification of concentrated virus was done by size exclusion chromatography. The results showed that peggylation is better method of concentration up to 603.75 µg/ml with 82.80 % recovery rate than ultra-filtration with 43.90 % followed by chromatography for purification. The PD50 was calculated in bovines at 24, 12, 6, 3 and 1.5 µg of FMDV Ag/dose and it revealed that antigen load of 1.98 µg is the dose, where the 50 % of inoculated animals showed the protective antibody level based upon percent inhibition through antibody detecting ELISA. According to the British pharmacopeia, the vaccine should contain 3PD50 which found equivalent to our findings about 6 µg/dose. The group of animal injected with 6/dose (3.23PD50) showed protective titer up to 20th week post priming.
No takes yet. Share an insight, caveat, or question.
Razak et al. (2023) studied this question. A purified FMDV type O vaccine concentrated via peggylation (82.8% recovery) maintained protective antibody titers in bovine calves for up to 20 weeks post-priming at a 6 µg/dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: